Replies to post #249743 on Biotech Values

[DewDiligence]

GRPH—>LENZ effective at tomorrow’s open, pursuant to previously announced reverse-merger:

https://www.businesswire.com/news/home/20240321281097/en

I’m generally bearish on the commercial prospects for a presbyopia eyedrop that works by inducing pupil contraction, and LENZ is not the only company developing such a product.